Video
Author(s):
Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.
Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.
According to Choyke, the rise of genomics in prostate cancer is an important development. However, genomic testing is not likely to be able to stand on its own without imaging. Imaging provides better sampling of the tumor, which leads to more accurate genomics, states Choyke.